Company Description
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.
The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 2, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Harith Rajagopalan |
Contact Details
Address: 3 Van de Graaff Drive, Suite 200 Burlington, Massachusetts 01803 United States | |
| Phone | 781 902 8800 |
| Website | fractyl.com |
Stock Details
| Ticker Symbol | GUTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001572616 |
| CUSIP Number | 35186V103 |
| ISIN Number | US35168W1036 |
| Employer ID | 27-3553477 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harith Rajagopalan M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Jay D. Caplan BSEE, MBA | Co-Founder, Chief Product Officer and President |
| Sarah S. Toomey Esq. | General Counsel and Corporate Secretary |
| Lara Smith Weber | Chief Financial Officer and Treasurer |
| Brian Luque | Head of Investor Relations and Corporate Development |
| Jon Fitzgerald | Senior Vice President of Regulatory, Quality and Clinical |
| Mike Zumdahl | Senior Vice President of Market Access and Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2026 | 8-K | Current Report |
| Jun 4, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 11, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |